

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1-40 (Cancelled).

41. (previously presented) A monoclonal antibody or antigen-binding portion thereof, wherein:

- a) the light chain variable region comprises a peptide with the sequence shown in SEQ ID NO:3 and the heavy chain variable region comprises a peptide with the sequence shown in SEQ ID NO:12;
- b) the light chain variable region comprises a peptide with the sequence shown in SEQ ID NO:4 and the heavy chain variable region comprises a peptide with the sequence shown in SEQ ID NO:13;
- c) the light chain variable region comprises a peptide with the sequence shown in SEQ ID NO:30 and the heavy chain variable region comprises a peptide with the sequence shown in SEQ ID NO:32; or
- d) the light chain variable region comprises a peptide with the sequence shown in SEQ ID NO:31 and the heavy chain variable region comprises a peptide with the sequence shown in SEQ ID NO:33.

42. (previously presented) The monoclonal antibody or antigen-binding portion thereof of claim 41, which comprises a heavy chain constant region selected from the group consisting of IgG₁, IgG₂, IgG₃, IgG₄, IgA, IgE, IgM, and IgD.

43. (previously presented) The monoclonal antibody or antigen-binding portion thereof of claim 41, which comprises a kappa or lambda light chain constant region.

44. (previously presented) The monoclonal antibody or antigen-binding portion thereof of claim 41, which is a Fab fragment, a F(ab')₂ fragment, or a single chain Fv fragment.

45. (cancelled)

46. (previously presented) The monoclonal antibody or antigen-binding portion thereof of claim 41, which is chimeric.

47. (previously presented) A pharmaceutical composition, comprising the chimeric monoclonal antibody or antigen-binding portion thereof of claim 46, and a pharmaceutically acceptable carrier, diluent, or excipient.

48. (previously presented) A method of treating obesity or a related disorder in a mammal, comprising administering to a patient in need thereof an effective amount of a chimeric monoclonal antibody or antigen-binding portion thereof of claim 46.

49. (previously presented) The method of claim 48, wherein said related disorder is selected from the group consisting of NIDDM, Prader-Willi syndrome, an eating disorder, hyperphagia, impaired satiety, anxiety, and a gastric motility disorder.

50. (previously presented) The method of claim 48, wherein said mammal is a human.

51. (previously presented) The method of claim 49, wherein said mammal is a human.